| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 51,049 | 89,397 |
| Depreciation | 1,365 | 923 |
| Amortization and accretion of marketable securities | -582 | 33 |
| Stock-based compensation | 22,390 | 14,351 |
| Impairment of right of use asset | 696 | - |
| Loss on disposal of property and equipment | 8 | - |
| Reduction in the carrying amount of right of use assets | 1,758 | 1,211 |
| Accounts receivable | 7,580 | - |
| Prepaid expenses and other current assets | 765 | 6,405 |
| Accounts payable, accrued liabilities and lease liabilities | 12,387 | 7,506 |
| Deferred revenue | -4,671 | -611 |
| Net cash provided by (used in) operating activities | 76,039 | 106,405 |
| Purchases of marketable securities | 224,494 | 200,569 |
| Purchases of property and equipment | 438 | 306 |
| Sales of marketable securities | 99,181 | 66,030 |
| Net cash used in investing activities | -125,751 | -134,845 |
| Proceeds from employee stock purchase plan | 1,002 | 370 |
| Proceeds from issuance of common stock upon exercise of stock options | 4,046 | 1,558 |
| Net cash provided by financing activities | 5,048 | 1,928 |
| Net decrease in cash, cash equivalents and restricted cash | -44,664 | -26,512 |
| Cash and cash equivalents at beginning of period | 128,779 | - |
| Cash and cash equivalents at end of period | 84,115 | - |
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)